A Rosati1, C Tetta2, J I Merello3, I Palomares3, R Perez-Garcia4, F Maduell5, B Canaud6, P Aljama Garcia7. 1. Department of Nephrology, Dialysis and Transplantation, Campo di Marte Regional Hospital, USL 2, Lucca, Italy. a.rosati@usl2.toscana.it. 2. EMEALA Medical Board, Fresenius Medical Care Deutschland GmbH, Else Kroener Strasse 1, Bad Homburg, Germany. ciro.tetta@fmc-ag.com. 3. Medical Department, Fresenius Medical Care, Madrid, Spain. 4. Department of Nephrology, Infanta Leonor University Hospital, Madrid, Spain. 5. Department of Nephrology, Hospital Clínic, Barcelona, Spain. 6. EMEALA Medical Board, Fresenius Medical Care Deutschland GmbH, Else Kroener Strasse 1, Bad Homburg, Germany. 7. Department of Nephrology, Reina Sofía University Hospital, Córdoba, Spain.
Abstract
INTRODUCTION: Optimizing anemia treatment in hemodialysis (HD) patients remains a priority worldwide as it has significant health and financial implications. Our aim was to evaluate in a large cohort of chronic HD patients in Fresenius Medical Care centers in Spain the value of cumulative iron (Fe) dose monitoring for the management of iron therapy in erythropoiesis-stimulating agent (ESA)-treated patients, and the relationship between cumulative iron dose and risk of hospitalization. METHODS: Demographic, clinical and laboratory parameters from EuCliD(®) (European Clinical Dialysis Database) on 3,591 patients were recorded including ESA dose (UI/kg/week), erythropoietin resistance index (ERI) [U.I weekly/kg/gr hemoglobin (Hb)] and hospitalizations. Moreover the cumulative Fe dose (mg/kg of bodyweight) administered over the last 2 years was calculated. Univariate and multivariate analyses were performed to identify the main predictors of ESA resistance and risk of hospitalization. Patients belonging to the 4th quartile of ERI were defined as hypo-responders. RESULTS: The 2-year iron cumulative dose was significantly higher in the 4th quartile of ERI. In hypo-responders, 2-year cumulative iron dose was the only iron marker associated with ESA resistance. At case-mix adjusted multivariate analysis, 2-year iron cumulative dose was an independent predictor of hospitalization risk. DISCUSSION: In ESA-treated patients cumulative Fe dose could be a useful tool to monitor the appropriateness of Fe therapy and to prevent iron overload. To establish whether the associations between cumulative iron dose, ERI and hospitalization risk are causal or attributable to selection bias by indication, clinical trials are necessary.
INTRODUCTION: Optimizing anemia treatment in hemodialysis (HD) patients remains a priority worldwide as it has significant health and financial implications. Our aim was to evaluate in a large cohort of chronic HDpatients in Fresenius Medical Care centers in Spain the value of cumulative iron (Fe) dose monitoring for the management of iron therapy in erythropoiesis-stimulating agent (ESA)-treated patients, and the relationship between cumulative iron dose and risk of hospitalization. METHODS: Demographic, clinical and laboratory parameters from EuCliD(®) (European Clinical Dialysis Database) on 3,591 patients were recorded including ESA dose (UI/kg/week), erythropoietin resistance index (ERI) [U.I weekly/kg/gr hemoglobin (Hb)] and hospitalizations. Moreover the cumulative Fe dose (mg/kg of bodyweight) administered over the last 2 years was calculated. Univariate and multivariate analyses were performed to identify the main predictors of ESA resistance and risk of hospitalization. Patients belonging to the 4th quartile of ERI were defined as hypo-responders. RESULTS: The 2-year iron cumulative dose was significantly higher in the 4th quartile of ERI. In hypo-responders, 2-year cumulative iron dose was the only iron marker associated with ESA resistance. At case-mix adjusted multivariate analysis, 2-year iron cumulative dose was an independent predictor of hospitalization risk. DISCUSSION: In ESA-treated patients cumulative Fe dose could be a useful tool to monitor the appropriateness of Fe therapy and to prevent iron overload. To establish whether the associations between cumulative iron dose, ERI and hospitalization risk are causal or attributable to selection bias by indication, clinical trials are necessary.
Authors: George R Bailie; Maria Larkina; David A Goodkin; Yun Li; Ronald L Pisoni; Brian Bieber; Nancy Mason; Lin Tong; Francesco Locatelli; Mark R Marshall; Masaki Inaba; Bruce M Robinson Journal: Nephrol Dial Transplant Date: 2013-10 Impact factor: 5.992
Authors: Ryan D Kilpatrick; Cathy W Critchlow; Steven Fishbane; Anatole Besarab; Catherine Stehman-Breen; Mahesh Krishnan; Brian D Bradbury Journal: Clin J Am Soc Nephrol Date: 2008-04-16 Impact factor: 8.237
Authors: Manfred Hecking; Ulrich Moissl; Bernd Genser; Hugh Rayner; Indranil Dasgupta; Stefano Stuard; Andrea Stopper; Charles Chazot; Franklin W Maddux; Bernard Canaud; Friedrich K Port; Carmine Zoccali; Peter Wabel Journal: Nephrol Dial Transplant Date: 2018-10-01 Impact factor: 5.992
Authors: Maria Luisa Agüera; Alejandro Martin-Malo; Maria Antonia Alvarez-Lara; Victoria Eugenia Garcia-Montemayor; Petra Canton; Sagrario Soriano; Pedro Aljama Journal: PLoS One Date: 2015-08-31 Impact factor: 3.240